Department of Chemistry, CB#3290, University of North Carolina, Chapel Hill, NC 27599, USA.
Curr Opin Chem Biol. 2010 Apr;14(2):262-8. doi: 10.1016/j.cbpa.2009.12.012. Epub 2010 Jan 12.
Nanoparticle-based therapeutics have received increasing attention, as these systems can alleviate many drawbacks of conventional therapy. Metal-organic frameworks (MOFs), a new class of hybrid materials composed of metal ions and organic bridging ligands, have emerged as a promising platform for drug delivery, owing to their high drug loadings, biodegradability, and versatile functionality. The bulk MOF materials can absorb and release large amounts of therapeutics including ibuprofen, procainamide, and nitric oxide. Scale-down of MOFs to the nanoregime yields nanoscale metal-organic frameworks (NMOFs) that are more applicable as delivery vehicles, such as selective delivery of cisplatin prodrugs. Although progress has been made in utilizing NMOFs for drug delivery, many improvements must occur before they can become viable nanotherapeutics.
基于纳米粒子的治疗方法受到了越来越多的关注，因为这些系统可以缓解传统治疗的许多缺点。金属-有机骨架（MOF）是一种由金属离子和有机桥连配体组成的新型混合材料，由于其高载药量、可生物降解性和多功能性，已成为一种很有前途的药物传递平台。大块 MOF 材料可以吸收和释放大量的治疗药物，包括布洛芬、普鲁卡因胺和一氧化氮。MOF 的缩小到纳米级得到纳米级金属-有机骨架（NMOF），更适用于作为药物载体，例如顺铂前药的选择性递送。尽管在利用 NMOF 进行药物传递方面已经取得了进展，但在它们成为可行的纳米治疗药物之前，还需要进行许多改进。
